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Abstract
Classic histology still represents the gold standard in tumor tissue analytics. However, two-dimensional analysis of
single tissue slides does not provide a representative overview of the inhomogeneous tumor physiology, and a de-
tailed analysis of complex three-dimensional structures is not feasible with this technique. To overcome this problem,
we applied multispectral fluorescence ultramicroscopy (UM) to the field of tumor analysis. Optical sectioning of
cleared tumor specimen provides the possibility to three-dimensionally acquire relevant tumor parameters on a cel-
lular resolution. To analyze the virtual UM tumor data sets, we created a novel set of algorithms enabling the fully
automatic segmentation and quantification of multiple tumor parameters. This new postmortem imaging technique
was applied to determine the therapeutic treatment effect of bevacizumab on the vessel architecture of orthotopic
KPL-4 breast cancer xenografts at different time points. A significant reduction of the vessel volume, number of vessel
segments, and branching points in the tumor periphery was already detectable 1 day after initiation of treatment.
These parameters remained virtually unchanged in the center of the tumor. Furthermore, bevacizumab-induced vessel
normalization and reduction in vascular permeability diminished the penetration behavior of trastuzumab–Alexa 750
into tumor tissue. Our results demonstrated that this new imagingmethod enables the three-dimensional visualization
and fully automatic quantification ofmultiple tumor parameters and drug penetration on a cellular level. Therefore, UM
is a valuable tool for cancer research and drug development. It bridges the gap between common macroscopic and
microscopic imaging modalities and opens up new three-dimensional (3D) insights in tumor biology.
Neoplasia (2014) 16, 1–13
Introduction
The quantitative description of tumor growth, angiogenesis, and
metastasis and also the treatment effects of new therapeutics on these
steps are essential to evaluate the full potential of anticancer com-
pounds. Therefore, different macroscopic and microscopic in vivo
and ex vivo imaging modalities are used to monitor the complex
interactions between a therapeutic drug and tumor biology [1,2].
Noninvasive in vivo imaging methods like computer tomography
[3,4], positron-emission tomography [5,6], magnetic resonance imag-
ing [7,8], fluorescence molecular tomography [9], and/or combinations
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thereof [10,11] offer the possibility to three-dimensionally monitor
various tumor parameters quantitatively with a spatial resolution
down to 50 μm [12–14]. However, to get more comprehensive infor-
mation regarding the mode of action of antitumor substances, it
is necessary to assess the different events of tumor progression at a
cellular resolution [15].
Intravital microscopy in living animals can overcome these limita-
tions and has provided cellular and/or molecular insights into tumori-
genesis [16,17], angiogenesis [18–20], tumor microenvironment [21],
and drug treatment response [15,22]. With a spatial resolution of
nearly 500 nm, minimal invasive intravital confocal laser scanning
microscopy and multiphoton laser scanning microscopy are eminently
suitable for three-dimensional real-time observation of multiple
biologic in vivo events down to cellular resolution. Nevertheless, the
slight penetration depth into tissue of below 500 μm and a small field
of view prevent entire tumor scanning [15,23–25]. Other intravital
microscopy techniques, such as optical coherence tomography and
optical frequency domain imaging, can measure a large field of view
with penetration depths beyond 1 mm and a spatial resolution of about
10 to 50 μm. However, their basic principle (optical interferometry)
of measuring the various optical scattering properties in tissue provides
only morphologic and physiological tissue information [26–29]. Direct
visualization of the labeled therapeutic agent and its penetration,
accumulation, and interaction with the tumor target structure is not
possible by using classic fluorochromes [9].
High spatial resolution over a large field of view coupled with the
ability to provide morphologic and biologic information can currently
only be provided by classic histology and immunohistochemistry
(IHC). Therefore, conventional histology is still the gold standard in
tumor analysis. Nevertheless, two-dimensional examination of a few
tumor tissue slices may not provide a representative and comprehensive
description of the complex and inhomogeneous tumor biology and is
therefore prone to misinterpretation. The three-dimensional recon-
struction of serial tissue slices is also not an appropriate alternative,
because it is a very laborious and time-consuming process and the
mechanical distortion of the tissue slices is difficult to overcome.
We applied multispectral fluorescence ultramicroscopy (UM) into
the field of tumor analysis to overcome the limitations of conventional
imaging techniques. For the last years, this ex vivo imaging method
has already proven itself and became more and more relevant in dif-
ferent areas of application such as embryonic development [30–34],
neuroscience [35–39], and immunology [40]. UM, as described by
Dodt et al. [35], uses focused laser light for a double-side, in-focus
plane illumination of the specimen (i.e., optical sectioning), and the
fluorescent light is detected perpendicular to the illumination axis
(Figure 1, A and B). Such principle of measurement prevents the
formation of out-of-focus light and reduces photobleaching to a
minimum. The problem of strong light absorption and scattering
in tissue is solved by optical clearing. Thus, specimen obtains high
transparency, and fluorescent light can traverse unrestricted for
several millimeters into tissue [35,38,41]. This can be achieved by
a chemical clearing procedure that removes the water from the bio-
logic sample and replaces it by a liquid having approximately the
same refractive index as solid tissue components, like lipids and pro-
teins [42,43] (Figure 1C ). UM in combination with optical tissue
clearing enables the three-dimensional measurement of large tumor
specimen up to 5 mm in diameter with a spatial resolution of about
5 μm [44]. By moving the transparent tissue sample vertical through
the planar laser beam, a z stack of serial optical sections is produced.
The virtual UM slices can subsequently be rendered as a maximum
intensity projection (MIP) or volume [44,45] (Figure 1D).
The virtual slices obtained from UM were compared with classic
two-dimensional (2D) fluorescence histology and IHC to confirm
the validity of this new method in tumor visualization. The results
demonstrate the anatomic and morphologic accordance between
both imaging techniques. To analyze the three-dimensional tumor data
sets obtained from UM, we developed a new software that possesses
excellent computational performance and enables a fully automatic
segmentation and quantification of different tumor characteristics, vas-
culature, and drug penetration parameter. After successful evaluation
and validation of this new imaging method, a proof-of-concept study
in an orthotopic breast cancer xenograft model was performed to three-
dimensionally quantify the antiangiogenic treatment effect of the
monoclonal antibody bevacizumab at different time points on a cel-
lular level. Furthermore, the influence of bevacizumab-induced vessel
normalization on the subsequent penetration of fluorescent-labeled
trastuzumab was also investigated.
Materials and Methods
Compounds and Labeling
The two monoclonal antibodies bevacizumab [recognizes and blocks
vascular endothelial growth factor A (anti-VEGF-A)] and trastuzumab
[recognizes and blocks human epidermal growth factor receptor 2 (anti-
HER2)] were provided by Roche Diagnostics GmbH (Penzberg,
Germany). Lectin from Bandeiraea simplicifolia, which has a high affin-
ity for terminal α-D-galactosyl and N-acetyl-α-D-galactosaminyl residues
and specifically binds to endothelial cells of the vessel network, was
acquired from Sigma-Aldrich (Taufkirchen, Germany). Lectin and tras-
tuzumab were labeled in-house with the fluorophore Alexa 647 and
Alexa 750 (Invitrogen, Darmstadt, Germany). They were attached
through monoreactive N-hydroxysuccinimide (NHS) ester to lysine
residues with a labeling ratio of three fluorophores per molecule.
Trastuzumab–Alexa 750 and lectin–Alexa 647 were purified by dialysis
and size-exclusion chromatography, and afterwards, surface plasmon
resonance analysis (GE Healthcare, BiaCore Life Sciences, Little
Chalfont, United Kingdom) was performed to measure the binding
characteristics of the antibody. There were no significant changes in the
kon and koff constants and the resulting affinity between labeled and
nonlabeled trastuzumab.
Cell Line and Culture
The human breast cancer cell line KPL-4 was kindly provided by
J. Kurebayashi (Kawasaki Medical School, Kurashiki, Japan). The
HER2-overexpressing tumor cells were incubated in Dulbecco’s mod-
ified Eagle’s medium (10% fetal calf serum and 2 mM L-glutamine)
at 37°C and 5% CO2 until they reached the final cell concentra-
tion for injection. The viability of the KPL-4 cells was assessed using
a Vi-CELL viability analyzer (Beckman Coulter, Krefeld, Germany)
and reached nearly 95%.
Tumor Xenograft
We generated tumor xenograft by orthotopic injections of KPL-4
tumor cells [3 × 106 cells/20 μl of phosphate-buffered saline (PBS)]
into the right penultimate inguinal mammary fat pad of anesthetized
female severe combined immunodeficiency (SCID) beige mice (age,
6-8 weeks; weight, 20-25 g; Charles River Laboratories, Sulzfeld,
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Germany). The tumors grew until they reached a tumor size of 60 mm3
(measured by caliper). General animal conditions were controlled daily,
and tumor volume and body weight were monitored once weekly.
All experimental study protocols were reviewed and approved by the
local government. The animals were handled according to guidelines
[Gesellschaft für Versuchstierkunde–Society of Laboratory Animals
(GV-SOLAS), Federation for Laboratory Animal Science Associations
(FELASA), and TierSchG], and the animal facility has been accredited
by the Association for Assessment and Accreditation of Laboratory
Animal Care International.
Figure 1. Basic principle of UM. (A) All UMmeasurements were performed with a commercially available light sheet microscope (LaVision
BioTec). The sketch illustrates the basic setup of the applied imaging system. (B and C) To overcome the problem of light absorption and
scattering, tumor specimen was chemically treated to change the tissue properties and make the sample optically transparent. The cleared
tumor was fixed into a sample holder and placed in the imaging chamber. Afterwards, a single layer was illuminated perpendicular to the
observation pathway by a thin laser light sheet. The emitted fluorescence light from the excited tumor plane is detected by a highly sensitive
charge-coupled device (CCD) camera. (D) By stepping the cleared tumor sample vertical (z-axis) through the laser sheet, multiple optical
sections are created. The received virtual slices of a specific tumor parameter, such as vessel architecture, can be rendered as MIP or
volume. (C) Scale bar, 500 μm. (The illustration of the UM imaging hardware from A and B was kindly provided from LaVision BioTec.)
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Treatment of Animals
When tumor size reached a volume of about 60 mm3, mice were
randomized and separated into two groups each consisting of 15 mice.
The first group (treatment) was treated i.v. with a single dose of 10 mg/
kg bevacizumab, and the second group (control) was injected i.v. with
PBS. One, 3, and 7 days after bevacizumab treatment, five mice from
the control and treatment groups were injected i.v. with 2 mg/kg
trastuzumab–Alexa 750. Six hours thereafter, all animals were treated
i.v. with 100 μg of lectin–Alexa 647 (100 μl), incubated for about
5 minutes, and then all tumors were explanted.
Fixation and Clearing
The explanted KPL-4 tumors were fixed in 10% buffered formalin
(VWR International, Ismaning, Germany) for about 12 hours at 4°C
in the dark and thereafter were dehydrated in a graded ethanol series
(3 × 70%, 2 × 95%, and 2 × 100% for 30 minutes each). These
steps were carried out using the Tissue-Tek VIP Vacuum Infiltration
Processor (Sakura Finetek, Heppenheim, Germany). The dehydrated
tumors were placed in a clearing solution consisting of one part
benzylalcohol and two parts benzylbenzoate (Sigma-Aldrich) and in-
cubated for 2 days at 4°C in the dark until the specimen became
optically transparent.
Acquisition of UM Data Sets
The cleared specimens were scanned with a commercial ultramicro-
scope (LaVision BioTec, Bielefeld, Germany). The standard magnifica-
tion of ×0.63 in combination with a ×2 objective lens (Mv PLAPO
2VC; Olympus, Hamburg, Germany) led to a final xy resolution of
5.1 μm, and the step size was set to the same value. We used this setting
to scan specimens with a diameter up to about 5 mm. The integrated
supercontinuum white light laser (SuperK EXTREME 80 mHz VIS;
NKT Photonics, Cologne, Germany) covers the entire wavelength
range of 400 to 2400 nm and enables the excitation of every commonly
used fluorophore. The different optical properties of vital and necrotic
tissue and the strong autofluorescence emission of the erythrocytes were
used to create a detailed illustration of the tumor morphology (excita-
tion range, 543/22 nm; emission range, 593/40 nm). Lectin–Alexa 647
(excitation range, 655/40 nm; emission range, 716/40 nm) and
trastuzumab–Alexa 750 (excitation range, 710/40 nm; emission range,
775/46 nm) showed a strong binding affinity to their target structure
and provided high signal intensities. Thus, the measurements were per-
formed with short exposure times (100-400 ms per slice) resulting in a
total acquisition time of about 30 to 40 minutes per tumor depending
on its size. Thereafter, the generated tagged image file format (TIFF)
slices were converted into Digital Imaging and Communications in
Medicine (DICOM) files and visualized using the OsiriX software
(Pixmeo, Bernex, Switzerland; open-source software). Furthermore,
ImageJ (open-source software) and GNU Image Manipulation Program
(GIMP; open-source software) were also used for the preparation of the
individual images and videos included in this manuscript.
Quantification of UM Data Sets
Quantification of the raw data was performed with a set of custom-
developed image analysis algorithms implemented as a “Definiens
Cognition Network Technology” rule set (Definiens AG, Munich,
Germany). To increase performance, the skeletonization and branch
point detection were written in C++ using the “Insight Segmentation
and Registration Toolkit” and loaded as a custom plug-in. With
Definiens requiring a six-pixel three-dimensional (3D) neighborhood, we
modified an existing Insight Segmentation and Registration Toolkit
implementation [46] so that the skeleton had no more diagonal pixels
(26 neighborhood). On one central processing unit (CPU) core (Intel
Xeon X5670 @ 2.93 GHz; Intel Corporation, Santa Clara, CA), it took
between 10 minutes [peak random-access memory (RAM) usage,
8 GB] and 2 hours (peak RAMusage, 20 GB) to quantify a single
tumor, depending on the tumor size and desired software settings.
Multiple engines can run simultaneously if enough hardware resources
and Definiens licenses are available, thus, enabling the timely and fully
automatic quantification of large groups with our software. For this
publication, the algorithm was configured to use the full resolution
of the UM data sets. Furthermore, vasculature with a distance to the
surface of the tumor smaller than 20% of the radius of a fictional
sphere with same volume as the tumor was defined as periphery.
Immunohistochemistry
Following 3D scanning, the cleared specimens were shortly incu-
bated in 100% xylene to remove residues from the clearing solution.
Then, tumor samples were incubated in paraffin (3 × 1 hour) and
embedded into paraffin blocks. All incubation steps were carried out
using the Tissue-Tek VIP Vacuum Infiltration Processor (Sakura
Finetek). For verification of the 3D imaging method, we compared
the optical sectioning results from UM with classic 2D histology.
Therefore, different layers (between the top and center) of a paraffin-
embedded KPL-4 tumor were randomly selected. Four serial tissue
slices with a thickness of 5 μm were created at each tumor layer. After-
wards, the obtained tissue slices were analyzed by conventional fluores-
cence histology [4′,6-diamidino-2-phenylindole (DAPI), lectin–Alexa
647, and trastuzumab–Alexa 750] and IHC [hematoxylin and eosin
(H&E), anti-cluster of differentiation 34 (CD34), and anti-HER2
staining]. In the preclinical efficacy study (day 7), three different layers
of the tumor (between the top and center) were randomly selected.
Four serial tissue slices with a thickness of 2.5 μmwere prepared at each
tumor region and analyzed by IHC (H&E, anti-CD34, anti-HER2,
and Ki67 staining). All tumor tissue slices were deparaffinized in a
descending xylene and ethanol series. Visualization of tumor tissue
was accomplished by DAPI mounting medium (Vector Laboratories,
Burlingame, CA) and classic H&E staining (Carl Roth, Karlsruhe,
Germany). Tumor vessels were stained with a primary rat anti-mouse
CD34 antibody (Hycult Biotech, Uden, Netherlands), followed by a
secondary goat anti-rat ImmPRESS HRP antibody (Vector Labo-
ratories) and colored with DAB (Dako, Hamburg, Germany). The
staining of the extracellular HER2 expression was performed using a
primary rabbit anti-human HER2 antibody (Thermo Fisher Scientific,
Rockford, IL), followed by a secondary goat anti-rabbit ZytoChem
Plus AP polymer antibody (Zytomed Systems, Berlin, Germany).
Slides were colored with permanent red (Zytomed Systems). Finally,
proliferating cells were detected using Ki67. The staining was performed
using a primary rabbit anti-human Ki67 antibody (Ventana Medical
Systems, Tucson, AZ), followed by the secondary OmniMap anti-
rabbit HRP antibody (Ventana), and colored with DAB (Ventana). All
tissue slides were mounted with a cover slide and subsequently digitalized
using a slide scanner with a magnification of ×20 (Pannoramic 250;
3DHISTECH, Budapest, Hungary).
Statistical Analysis
The analysis was performed using the JMP software (version 8.0.2.2;
SAS Institute, Cary, NC). We used a classic two-tailed, unpaired
Student’s t test to determine significant differences for each time point.
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We considered P values of ≤.05 as significant. The significance levels
are indicated by asterisks (*P < .05, **P < .01, and ***P < .001). All
data are presented as means ± SD.
Results
Visualization of Tumor Morphology
For the visualization of tumor morphology, the cleared tumor
specimen were excited with green laser light (λ = 543/22 nm), which
induced a strong tissue autofluorescence signal. The variation of light
absorption caused by differences in the structural compositions of the
tissue resulted in autofluorescence-rich contrast, thereby allowing tissue
components to be roughly differentiated (Figure 2A). We observed
that the necrotic areas had a weaker autofluorescence signal because
of lower tissue density and were therefore seen as darker regions. This
allowed us to differentiate vital from necrotic regions in the tumor
tissue (Figure 2B). Conventional H&E staining verified these necrotic
areas of tissue (Figure W1). Erythrocytes had very high autofluores-
cence emission levels at this wavelength range, distinguishing them
clearly from the surrounding tissue. This information was used to
visualize their distribution pattern and also for identifying the presence
of blood pools in the tumor tissue (Figure 2C ). Compared to con-
ventional 2D histology where only a few tissue slices are commonly
Figure 2. Visualization of tumor morphology, vessel architecture, and drug penetration. (A) The detection of tissue autofluorescence
provides detailed information about tumor morphology. (B) The strong tissue contrast allowed the differentiation between vital (yellow
arrowhead) and necrotic (white arrowhead) tumor areas. (C) Erythrocytes have a strong autofluorescence signal in the autofluorescence
range (white arrowhead). As a result of this, their distribution and accumulation in the tumor tissue were clearly visible. (D) Volume render-
ing of the tumor morphology. (E) The complex and chaotic structures of the lectin–Alexa 647–stained tumor vessels were clearly visible
in the MIP of 30 virtual single UM slices. (F and G) The blow-up images of the MIP from (E) showed the heterogeneity of the tumor vessel
architecture. Some tumor areas possess a very dense vascularization (G), whereas others provide only a sparse or absent vasculature (F).
(H) Volume rendering of the vessel architecture. (I) The penetration and binding behavior of trastuzumab–Alexa 750 after an incubation
time of 6 hours were visualized in the MIP of 30 virtual single UM slices. (J and K) The inhomogeneous penetration and distribution of
the labeled antibody in the tumor tissue were clearly visible in the blow-up images from I. Most parts of the tumor areas were extensively
penetrated (K), although there were tumor areas that had only a weak or completely absent antibody signal (J). (L) Volume rendering of
the antibody penetration. (A–C) Single slice, 5-μm diameter. (E–G and I–K) MIP, 30 slices with 5-μm diameter per slice. Scale bar,
250 μm and 100 μm (blowup).
Neoplasia Vol. 16, No. 1, 2014 3D Tumor Analysis by Multispectral Ultramicroscopy Dobosz et al. 5
analyzed, UM enables the three-dimensional visualization of the
tumor morphology (Figure 2D and Video W1A).
Visualization of Tumor Vessel Architecture
Lectin–Alexa 647, which binds specifically to the sugar residues of
vascular endothelial cells, was injected i.v. into a KPL-4 tumor–bearing
animal. After tumor explantation and tissue clearance, we measured
the specimen three-dimensionally with UM. High binding specificity
of the vessel marker in combination with the fluorescent properties of
the applied near-infrared fluorochrome resulted in a high signal-to-
noise ratio, and thus, the tumor vasculature was clearly visible in the
virtual UM slices. A MIP of 30 optical vascular slices clearly visualized
the chaotic, irregular, and dramatically branched vascular structures
typical of a tumor [15] (Figure 2E). The heterogeneity of the vascular
Figure 3. Combination of different tumor parameters. (A) The overlay of the vascular (green) and antibody (red) channels showed that
the differing density of the vessels leads to an uneven distribution of the antibody. (B) Tumor areas with low vascular density showed only
very slight or absent antibody signals, whereas (C) in areas with a high vascular density, there was strong and homogeneous antibody
penetration. (D) The combination of the tissue (gray) and vascular information clearly showed the correlation between vascular density
and the development of necrosis. (E) Areas with low or absent vascular connections developed necrosis, whereas (F) those with a high
vascular density had a solid tissue structure. In the latter, erythrocytes (white spots) were also more prevalent. (G) The overlapping of the
tissue and antibody channel showed the penetration of the trastuzumab–Alexa 750 in the different areas of tissue. (H) Necrotic areas of the
tumor were hardly penetrated by the labeled antibody at all. (I) Solid tumor tissue, however, demonstrated very strong and homogeneous
antibody penetration and distribution. (A–I) MIP, 30 slices with 5-μm diameter per slice. Scale bar, 250 μm and 100 μm (blowup).
6 3D Tumor Analysis by Multispectral Ultramicroscopy Dobosz et al. Neoplasia Vol. 16, No. 1, 2014
network was also clearly demonstrated. Some tumor areas displayed
only sparse or absent vascular density (Figure 2F ), whereas vascu-
larization in other regions was high (Figure 2G ). The complexity of
the whole tumor vessel architecture at cellular level was perfectly
shown in the 3D volume rendering (Figure 2H and Video W1B and
Video W2). Furthermore, if it is not necessary to capture the entire
vasculature of the tumor, local xy resolutions can be increased up to
0.5 μm. This allowed us to differentiate between regular blood vessels
and tumor vessels (Figure W2A), and even individual vascular
endothelial cells could be clearly displayed (Figure W2B).
Visualization of Antibody Penetration in Tumor Tissue
Trastuzumab–Alexa 750, which has a high affinity for the extracellular
domain of HER2, was injected i.v. into the HER2-overexpressing KPL-4
xenograft model, to monitor the antibody penetration and binding be-
havior in tumor tissue. An MIP of 30 optical slices showed the hetero-
geneous penetration and binding of the labeled antibody after 6 hours
of injection (Figure 2I). Some areas of the tumor had only very low or
no antibody signals (Figure 2J ), and in other regions, very strong and
homogeneous trastuzumab distribution was detected (Figure 2K ). In
addition, UM opens up the possibility to three-dimensionally visualize
drug penetration inside a whole tumor at a cellular level (Figure 2L and
Video W1C).
Combination of Different Tumor Parameters
UM allows the simultaneous visualization of antibody penetration
and tumor vessel architecture. The relationship between the density
and morphology of the tumor vessels and the antibody penetration
was clearly demonstrated (Figure 3A and Video W3A). Highly vas-
cularized areas of the tumor displayed very strong and homogeneous
antibody distribution, whereas areas with low vascular density were
only slightly or not at all penetrated (Figure 3, B and C ). Morpho-
logic abnormalities or changes in the tumor tissue (such as necrosis)
could also be correlated to the vascular network (Figure 3D and
Video W3B). Tissue areas with a vascular density below a certain level
were apparently no longer supplied with oxygen and/or nutrients,
inevitably leading to tissue necrosis (Figure 3E ). Accumulation of
RBCs in the tumor tissue allows an indication of vessel permeability
Figure 4. Validation of UM data sets by conventional histology. (A) Optical slicing of the cleared KPL-4 tumor sample was performed by
UM to receive a stack of single virtual tumor tissue slices. Thereafter, the tumor specimen was paraffin embedded and conventionally
cut into serial tissue slices. Different targets of the tumor tissue slices were stained by classic IHC. The virtual slices of the different
fluorescence channel were compared to conventional histology to show the validity of UM. (B–D) The direct comparison between tumor
tissue information from the virtual autofluorescence UM slice (B) and conventional fluorescence histology (C; DAPI) and classic IHC
staining (D; H&E) showed nearly identical tissue structures. (E–G) The virtual UM slice of the lectin–Alexa 647–stained tumor vasculature
from E provided also a great morphologic accordance to the conventional fluorescence histology (F; lectin–Alexa 647) and classic IHC
vessel staining (G; anti-CD34). (H–J) The penetration and binding behavior of trastuzumab–Alexa 750 in the tumor tissue after 6 hours of
incubation showed nearly identical distribution pattern in virtual UM (H) and conventional fluorescence histology (I). (J) The IHC staining
of the extracellular HER2 receptor domain (anti-HER2, SP3) provided the expression level of all available HER2 tumor cell receptors. (B–J)
Single slice, 5-μm diameter. Scale bar, (A) 500 μm and (B–J) 250 μm.
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(Figure 3F ). The combination of tissue information with antibody
penetration indicated how the drug was penetrating various tissue areas
(Figure 3G and Video W3C). We further observed that trastuzumab–
Alexa 750, as a tumor-targeting drug, generally penetrated only margin-
ally into necrotic areas of the tissue (Figure 3H ), whereas solid tumor
tissue with sufficient vascular density had a very strong antibody signal
(Figure 3I).
Validation of UM Data Sets by Conventional Histology
Because UM was being used for the first time for multispectral
analysis of postmortem tumor tissue, we validated the virtual slices
using classic 2D histology (Figure 4A). Therefore, subsequent to UM
measurement, a cleared KPL-4 xenograft tumor was paraffin embedded
and conventionally cut at different tumor regions. Four serial tissue
slices were created at each plane. The first tumor tissue slice was DAPI
stained, and afterwards, the including fluorescence signals (DAPI,
lectin–Alexa 647, and trastuzumab–Alexa 750) were visualized (Fig-
ure 4, C , F , and I). Furthermore, H&E and different IHC stainings,
such as anti-CD34 and anti-HER2, were performed with the other
serial slices (Figure 4, D, G , and J ). The direct comparison between
the virtual and conventionally prepared slices of the same tumor tissue
layer showed an excellent correlation. Both the tissue morphology and
vascular architecture of the tumor and the penetration and binding of
the therapeutic antibody were shown to be identically rendered with
UM and classic histology (Figure 4, B–J).
Quantification of UM Data Sets
To analyze the different virtual UM tumor data sets, we created a
novel set of algorithms enabling the fully automatic segmentation
and quantification of multiple tumor composition, vessel architecture,
and drug penetration parameters without any manual user interference.
The first step was a segmentation of the tumor sample from the back-
ground using automatic thresholding techniques on the autofluores-
cence channel (Figure 5, A and B). The software then generated a
binary image of the vessels inside the tissue region. Vessel-free areas
inside the tumor with a minimum distance to the surrounding vas-
culature were classified as necrotic tissue (Figure W3, A–C ). This
parameter was determined on the basis of the results of conventional
histology and enabled the 3D quantification of tumor necrosis (Fig-
ure 5, C and D). Next, the skeletonization of the binary vascular
tree was executed using an iterative 3D-thinning algorithm [47].
Thereafter, a 3D kernel found the branch points and segments (Fig-
ure 5, E and F). The individual skeleton segments were then extended
back to the full vessel diameter using a pixel-based object-growing
Figure 5. Quantification of UM data sets. (A) The raw data from the tissue channel were used to determine the total tumor volume.
(B) Segmentation between tissue and background. (C and D) Three-dimensional visualization of the volume (blue) and necrotic areas
(yellow) of the tumor. (E) The virtual tissue slices formed the basis of the vascular analysis. (F) Three-dimensional segmentation of the
binary vascular tree. (G and H) Growth of the skeletal segments and quantification of the different segments and branching points. The
different diameters of the vascular segments are represented by different colors. (I) The information from the antibody channel is used
to determine the total signal and penetration of trastuzumab–Alexa 750. (J) We used the color-coded segmented 3D distance map
shown here to calculate the penetration of the antibody from the tumor margin to its center. (K and L) We used another color-coded
3D distance map to calculate the penetration of the antibody from the tumor vessels into the surrounding tissue. (A, B, E, F, and I–L)
Single slice, 5-μm diameter. Scale bar, 250 μm.
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algorithm that ensured that the enlarged segments were connected
to each other only by their branch points. Multiple single-segment
parameters and aggregate vessel statistics were then calculated for
the whole tumor. This allowed the color-coded three-dimensional
visualization of different vessel features, for example segment diameter
(Figure 5, G and H).
To determine the penetration behavior of a fluorescence-labeled
substance (e.g., trastuzumab–Alexa 750) into the tumor tissue, the
software initially subtracted the computed background signal from
the raw data. Thereby, the accumulated antibody signal and the average
signal intensity of trastuzumab–Alexa 750 in the entire tumor area were
calculated (Figure 5I). Furthermore, the distribution pattern of the fluo-
rescence signals within the sample was analyzed. For this, the software
calculated three-dimensional distance maps to the tumor border and
the nearest vessel and then segmented these into different color-coded
bins (Figure 5, J–L). Thereafter, the antibody signal intensities were
quantified in every bin, resulting in penetration gradients of the anti-
body (FigureW3,D–H). This process allowed us to analyze the penetra-
tion behavior of the antibody from the tumor margins to its center
(Figure 5J) and the penetration behavior of the therapeutic drug from
the vessels into the surrounding tumor tissue (Figure 5, K and L).
Monitoring of Antiangiogenic Treatment Response
Having demonstrated the utility of this new imaging method for
the visualization and automatic quantification of different tumor
parameters and drug penetration, we performed a preclinical efficacy
study to examine the effect of an antiangiogenic compound in the
KPL-4 xenograft model. The treatment group received a single dose
of bevacizumab, and control mice were treated with PBS. After 1, 3,
and 7 days, respectively, we selected five animals from both groups
and injected trastuzumab–Alexa 750. Six hours later, lectin–Alexa
647 was applied to tag the tumor vessels. Subsequently, the tumors
were explanted, cleared, and scanned by UM. Afterwards, the
tumors were embedded in paraffin, and conventional histology and
IHC were performed.
The UM results of the tumor vessels in the control group showed
chaotic and inhomogeneous vascularity. Large sections of the tumor
periphery appeared to be highly vascularized, whereas some areas
of the tumor had only isolated vessels, and others were completely
devoid of vascularization (Figure 6A). An effect of bevacizumab on
the tumor vessels was already detectable 1 day after initiation of
treatment. We found a significant reduction of the vessel volume
(P < .01), number of vessel segments (P < .01), and branching points
(P < .01) in the tumor periphery, whereas these parameters remained
virtually unchanged in the center of the tumor (Figure 6, D–F ).
The treatment also resulted in vessel normalization, which confirms
extensive studies performed by Rakesh Jain’s group [48], and the
vessel architecture appeared to be more homogeneous. Both effects
became more pronounced as the length of treatment was extended
(Figure 6B). Bevacizumab exerted its antiangiogenic effect signifi-
cantly on vessels with a diameter between 10 and 30 μm, whereas
vessels greater than 30 μm were not significantly affected by the
therapy (Figure W4). The normalized vessel network obviously allowed
an improved blood supply to the tumor, thereby reducing the inter-
stitial fluid pressure [49], and thus provides a more constant supply
of oxygen and nutrients [15]. In concordance to this, we found pro-
liferating tumor cells evenly distributed in the tissues analyzed 7 days
after start of treatment with bevacizumab (Figure W5; H&E and
Ki67). Compared to the PBS-treated mice, necrotic areas were re-
duced by an average of 69% in the bevacizumab-treated tumors.
In contrast to these changes, we did not observe a significant reduc-
tion of tumor volume even after 7 days of treatment (Figure 6C ).
Drug Penetration after Antiangiogenic Pretreatment
Besides analyzing the direct therapeutic effect of bevacizumab on
the vascular architecture and the tumor volume, we also investigated
the influence of an antiangiogenic pretreatment on the subsequent
penetration of a tumor-targeting antibody into tumor tissue. There-
fore, we combined the UM information of tumor vasculature from
the previous chapter with the penetration behavior of trastuzumab–
Alexa 750.
Control mice treated with PBS demonstrated a strong penetration
of trastuzumab–Alexa 750 in highly vascularized tumor areas
(Figure 7A). In contrast, explanted tumors from mice pretreated with
bevacizumab showed a significant reduction in the trastuzumab–
Alexa 750 penetration (P < .001) 1 day after initiation of treatment
(Figure 7B). Furthermore, the antiangiogenic therapy decreased sig-
nificantly the penetration of trastuzumab–Alexa 750 from the tumor
border to its center (Figure 7, C and D) and also the penetration
from the tumor vessels into the surrounding tumor tissue (Figure 7,
E and F ). These results demonstrated that bevacizumab diminishes
deposition of trastuzumab in the tumor tissue for all tested time
points (Figure 7G ). To ensure that the antiangiogenic pretreatment
did not affect the HER2 expression level, we performed IHC stain-
ing on tumor tissue sections. Both study groups (PBS and bevacizu-
mab) demonstrated high extracellular HER2 expression (3+) on the
surface of the KPL-4 tumor cells (Figure W5; HER2), and thus, we
were able to rule out an internalization and/or shedding of the extra-
cellular domains from the tumor cell surface.
Therefore, the diminished penetration of trastuzumab–Alexa 750
can only be attributed to the reduction in vascular permeability pro-
moted by bevacizumab. The reduced pore size in the normalized
tumor vessels made it more difficult for trastuzumab–Alexa 750 to
penetrate due to its high molecular weight, and as a result, more
of the antibody is confined to the vessel compartment [18,50]
(Figure W6).
Discussion
In this work, we applied multispectral fluorescence UM to the field
of tumor analysis and thus were able to create unprecedented three-
dimensional and quantitative insights into whole tumors with cellu-
lar resolution.
This ex vivo imaging technique uses optical tissue clearing in com-
bination with near-infrared fluorochromes to reduce light absorption
and scattering in tissue to a minimum and therefore increase the pen-
etration depth and image quality. The resultant high signal-to-noise
ratio enabled a fast measurement of tumor samples up to 5 mm in
diameter with an almost isotropic resolution of 5.1 μm. The applied
optical clearing procedure did not give rise to any appreciable reduc-
tion of the fluorescence signals in the tumor samples (Figure W7)
and had also no recognizable influence on the performance of
conventional IHC staining. Various routine tissue stainings, such
as H&E, Ki67, CD34, and HER2, could be conducted without
any problems subsequently after UM measurements and illustrated
perfect staining results. Furthermore, a direct comparison of the
virtual data sets created by UM and conventional 2D histology dem-
onstrated an excellent morphologic and anatomic correlation between
both techniques.
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Figure 6.Monitoring of antiangiogenic treatment response. (A and B)We visualized the vascular development of KPL-4 tumors in the control
and treatment groups for a period of 7 days using UM. Treatment with bevacizumab reduced, homogenized, and normalized the tumor
vasculature, whereas the vessel network of the control group remained unchanged. The effect was proportional to the length of treatment
(days 1, 3, and 7; n = 5 per day). MIP, 60 slices with 5-μm diameter per slice. Scale bar, 250 μm and 100 μm (blowup). (C) Quantification
results of the total, vital, and necrotic tumor tissue volume for the control and treatment groups at different time points. Even after 7 days
of treatment, there was no significant reduction in tumor volume. (D–F) The quantification of the UM data sets showed a significant reduc-
tion of vessel volume (D), vessel segments (E), and branching points (F) in the tumor periphery, whereas these parameters remained virtually
unchanged in the core of the tumor [relative vessel volume (%) = (tumor vessel vol/total tumor tissue vol) * 100]. Vasculature with a dis-
tance to the surface of the tumor smaller than 20% of the radius of a fictional sphere with the same volume as the tumor was defined
as periphery. Control group, days 1, 3, and 7; n = 5 per day. Treatment group, days 1, 3, and 7; n = 5 per day. All values are given as
means ± SD. *P < .05, **P < .01, and ***P < .001; t test.
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Figure 7. Monitoring of antibody penetration after antiangiogenic pretreatment. (A and B) The control group showed a strong penetra-
tion behavior of trastuzumab–Alexa 750 in the KPL-4 xenograft (A), whereas the labeled antibody penetration was significantly reduced
by antiangiogenic pretreatment with bevacizumab (B). MIP, 60 slices with 5-μm diameter per slice. Scale bar, 250 μm and 100 μm
(blowup). (C–G) Pretreatment with bevacizumab led to a significant reduction in trastuzumab–Alexa 750 penetration (G). This was seen
in both the reduced penetration of trastuzumab–Alexa 750 from the tumor border to its center (C and D) and in the reduced labeled
antibody penetration from the tumor vessels into the surrounding tumor tissue (E and F). Control group, blue; mean of days 1, 3, and 7;
n = 5 per day. Treatment group, red; mean of days 1, 3, and 7; n = 5 per day. All values are given as means ± SD. *P < .05, **P < .01,
and ***P < .001; t test.
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The fully automated 3D analysis of the various UM data sets, such
as tumor morphology, vessel architecture, and drug penetration, was
carried out with a novel set of custom-developed image analysis algo-
rithms that were implemented into a quantification software. This
new quantification tool enables the automatic segmentation of differ-
ent tumor parameters from each fluorescence channel and analyzed
their specific value without any manual user interference. The com-
plete quantification process for all parameters took less than 2 hours
per tumor on a single processor, whereas the number of concurrent
tumor quantifications is only limited by available hardware resources.
Multiple engines can run simultaneously if enough hardware re-
sources and Definiens licenses are available, thus, enabling the timely
and fully automatic quantification of large groups. This aspect allows
a very rapid, detailed, and cost-efficient implementation and analysis
of preclinical studies on a large scale.
After successful validation, we applied this new imaging method
in preclinical cancer research for the three-dimensional and quantita-
tive analysis of the therapeutic treatment effect of bevacizumab on
the tumor vasculature. We further investigated the influence of in-
duced vessel normalization on the subsequent penetration behavior
of fluorescent-labeled trastuzumab. Besides the determination of the
total, vital, and necrotic tumor tissue volume, a quantitative analysis
of the tumor vessel architecture was for the first time realized in a
three-dimensional way at cellular resolution. A significant reduction
of the tumor vessel volume, number of vessel segments, and branching
points could be detected by UM even 1 day after initiation of treat-
ment (P < .01). The antiangiogenic treatment effect of bevacizumab
on vessel diameter between 10 and 30 μm was mainly executed in the
tumor periphery (P < .01), whereas the established vasculature in the
tumor center remained virtually unchanged. Furthermore, strong nor-
malization and homogenization of the vessel network became more
pronounced as the length of treatment extended.
It has been proposed by others that vessel normalization improves
the supply of blood, nutrients, and oxygen into the tumor [15], reduces
the interstitial fluid pressure [49], and thereby improves the delivery
and penetration of therapeutics into tumor tissue [49,51,52]. In con-
trast to this, our results showed that bevacizumab-induced vessel
normalization and reduction in vascular permeability diminished the
penetration behavior of trastuzumab–Alexa 750 into tumor tissue.
These results are in accordance to published data [50,53]. In con-
sequence of this, a clear rational for scheduling of large therapeutic
drugs, such as proteins and antibodies, in combination treatment with
antiangiogenic compounds can be optimized. To receive optimal tumor
penetration of both therapeutic agents, the tumor cell–targeting anti-
body must be injected before starting the antiangiogenic therapy.
The work presented here illustrates the huge potential of this new
ex vivo imaging method for the three-dimensional and fully quantitative
endpoint analysis of tumors at cellular resolution. By assessing multiple
tumor parameters simultaneously, UM enables a unique, accurate, and
comprehensive 3D overview of the heterogeneous tumor biology and
drug penetration. In preclinical cancer research and drug develop-
ment, we consider UM as a new link between current in vivo imaging
methods and classic two-dimensional histology. The outstanding com-
bination possibility and complementary behavior of fluorescent-based
in vivo and ex vivo imaging techniques and classic histology enable a
detailed pharmacokinetic and pharmacodynamic analysis of tumor
biology and drug behavior from a macroscopic down to a microscopic
scale. Comprehensive information about these complex mechanisms
will help to efficiently design new drug formats and select suitable can-
didates more quickly. Moreover, because fluorescent-labeled proteins
are becoming more and more relevant for clinical applications regarding
tumor diagnosis, either for intraoperative or catheter-based procedures,
we assume that UM can be used for three-dimensional analysis of
human tissue samples in the near future [54,55].
In summary, multispectral fluorescence UM in combination with
our novel automatic quantification software is a new postmortem
imaging technique that provides the possibility for three-dimensional
and fully quantitative endpoint analysis of multiple tumor parameters
and drug penetration at cellular resolution. These unique and holistic
three-dimensional insights will help to understand the complex tumor
biology in more detail and should accelerate the various stages of
preclinical drug development.
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Figure W1. Necrosis evaluation. The morphologic comparison of
the virtual tissue slice from the UM (A) and classic H&E staining
(B) showed an excellent correlation. Both methods clearly differ-
entiated the necrotic tissue areas (white arrowhead) from the solid
tissue areas (yellow arrowhead) of the tumor. Single slices, 5-μm
diameter. Scale bar, 250 μm.
Video W1. Volume rendering of (A) tumor tissue, (B) tumor vessels, and (C) trastuzumab–Alexa 750 penetration in KPL-4 breast tumor.
Video W2. Volume rendering of tumor vessel architecture in KPL-4 breast tumor.
Video W3.MIP (30 slices) overlay of (A) tumor vessels (green) on trastuzumab–Alexa 750 penetration (red), (B) tumor vessels (green) on
tumor tissue (gray), and (C) trastuzumab–Alexa 750 penetration (red) on tumor tissue (gray) in KPL-4 breast tumor.
Figure W2. Vessel morphology. (A) If we concentrate only on
smaller sections of the tumor, the local xy resolution can be
increased to a value of 0.5 μm. This allowed us to visualize the mor-
phologic transition from regular (white arrowhead) to tumor (yellow
arrowhead) vascular structures. (B) The digital blowup of the image
data from A allowed even single epithelial cells on the surface of the
vessels to be visualized (white arrowhead). MIP, (A) 30 slices with
5-μm diameter per slice and (B) 5 slices with 5-μm diameter per
slice. Scale bar, (A) 25 μm and (B) 5 μm.
Figure W3. Detection of necrotic tissue areas and quantification of drug penetration. (A) The contrast differences of the tumor tissue allow a
rough differentiation between vital and necrotic (white arrowhead) regions. (B) To detect and quantify the necrotic tissue areas, a binary
image of the segmented vessels (red) was overlaid on the tissue channel from the UM. We classified tumor areas with no vessels and a
minimum distance of 200 μm to the surrounding vasculature as necrotic. We then used a growing strategy to extend those areas up to
a minimum vascular distance of 125 μm (green). Scale bar, 250 μm and 100 μm (blowup). (D) We combined the UM information from the
tumor vessel (green) and the antibody channel (red) to determine the antibody penetration from the tumor vessels into the surrounding
tissue. (E) The vessels were three-dimensionally detected in the whole tumor region. (F and G) After vessel detection, we created a
3D distance map in the tumor region and divided it into individual bins. The different bins are displayed color-coded to allow easy visual
differentiation. We then calculated the antibody signal in the various bins. (H) The resulting signal intensity gradient reflects antibody
penetration from the tumor vessels into the surrounding tumor tissue. The analysis of antibody penetration from the margin of the tumor
to its center follows the same principles. (A–C) MIP, 30 slices with 5-μm diameter per slice. Scale bar, 50 μm.
Figure W4. Vessel segment diameter distribution. Diameter distribution of the vascular segments in the tumor periphery (A) and in the
tumor center (B) of the control and treatment groups. Treatment with bevacizumab led primarily to a significant reduction in the number
of segments located inside the tumor periphery (A), whereas the effect in the tumor center was only marginal (B). Control group, days 1,
3, and 7; n = 5 per day. Treatment group, days 1, 3, and 7; n = 5 per day. All values are given as means ± SD. *P < .05, **P < .01, and
***P < .001; t test.
Figure W5. Histologic comparison of the control and treatment groups on day 7. (A) The H&E and Ki67 staining of the control group
revealed large areas of necrosis in the tumor tissue (yellow arrowhead). Outside the necrotic tissue areas, the Ki67 staining showed a
strong and homogeneous tumor cell proliferation (brown tumor cells). These solid tissue areas also provided a high HER2 expression
level on the tumor cell surface. (B) In contrast, the treatment with bevacizumab reduced the necrotic areas in the tumor tissue as shown
in the H&E and Ki67 staining. Up to this point, the treatment had no effect on the proliferation rate of the tumor cells. The Ki67 staining
showed a strong and homogeneous proliferation pattern similar to the untreated control group. Furthermore, bevacizumab had no direct
effect on the HER2 receptor expression level; therefore, the reduced penetration behavior of trastuzumab–Alexa 750 can be only attributed
to the antiangiogenic treatment effect. Single slices, 2.5-μm diameter. Scale bar, 500 μm and 50 μm (blowup).
Figure W6. Penetration behavior of trastuzumab–Alexa 750 after bevacizumab pretreatment. (A) The 7-day treatment with bevacizumab led
to a reduction, normalization, and homogenization of vascular architecture and significantly reduced trastuzumab–Alexa 750 penetration.
(B) The blowup of A clearly shows the reduced penetration of trastuzumab–Alexa 750 from the tumor vessels. In the spectral decomposition
of the image from B into the vessel (C) and antibody channel (D), higher levels of residual trastuzumab–Alexa 750 (yellow arrowhead) were
detected in the normalized tumor vessels. MIP, 60 slices with 5-μm diameter per slice. Scale bar, 250 μm and 100 μm (blowup).
Figure W7. Influence of tumor tissue fixation and optical clearance on the fluorescence signal intensity. (A) HER2-overexpressing non-small
cell lung cancer (NSCLC) tumor–bearing mouse was injected i.v. with 2 mg/kg trastuzumab–Alexa 750, and after an incubation time of
24 hours, epifluorescence in vivo imaging (Maestro; PerkinElmer, Waltham, MA) was performed. Thereafter, the tumor was explanted
and cut into three nearly similar tissue pieces. One tissue section was shortly incubated in liquid nitrogen and stored at a temperature of
−80°C. The other two tumor tissue sections were incubated overnight in formalin and dehydrated in a graded ethanol series. Subsequently,
one tissue section was incubated in xylene, and the other part was placed for 2 days in a benzylalcohol-benzylbenzoate clearing solution.
Afterwards, both tumor sectionswere embedded in paraffin. Serial tissue slices were prepared from all tumor tissue samples, and the signal
intensity of trastuzumab–Alexa 750 was analyzed by fluorescence microscopy (Nuance; PerkinElmer). (B) The fluorescence signal in the
cryoslice showed clear and strong binding of trastuzumab–Alexa 750 to the NSCLC cells, and a maximum signal intensity of 1118 counts
was detected in the measurement region. (C and D) The maximum fluorescence signal intensity of the labeled antibody in the paraffin
(C) and cleared tumor tissue slice (D) was only slightly reduced to 1057 and 1092 counts compared to the cryoslice. The signal reduction
can be attributed to the smaller diameter of both tissue slices (2.5 μm vs 6 μm for the cryoslice). Identical binding pattern of trastuzumab–
Alexa 750 to the tumor cells was clearly visible. No recognizable differences between the cryo-, paraffin, and cleared tumor tissue slices
regarding fluorescence signal intensity were detectable. Single slices, (B) 5-μm diameter and (C and D) 2.5-μm diameter.
